Women have historically favored contraception. For good reason, women have access to a variety of contraceptive methods, whereas men have access to far fewer and less well-known options. However, that might soon alter. A hormone-free tablet created by American researchers has shown 99% effectiveness in mice.
Until now, contraceptive methods for men have suffered from problems of acceptance of treatment by men and a lack of investment in research. Scientists had always focused on testosterone to develop a male pill.
"In recent years, among the various avenues of research, there have been anti-testosterone treatments. But the problem with these treatments was the side effects, with low libido, erection problems, fatigue", declared France Inter, Michael Grynberg, head of the gynecology-obstetrics department at Antoine-Béclère Hospital.
However, the pill might someday pass for the male sex. A team of American scientists announced on March 23 that they had created a male contraception procedure that would have no negative side effects. The uniqueness of this medicine? Hormones are not how it functions.
A drug called YCT529 targets the RAR-alpha protein to decrease sperm production.
The researchers investigated more than 100 compounds to find a therapeutic candidate that targets a protein known as "retinoic acid receptor alpha (RAR-alpha)" in order to achieve this finding, which may allow for more equitable sharing of the mental burden associated with contraception. This protein, according to scientists, has a role in sperm and cell growth.
Following their experiments, the scientists created a chemical known as "YCT529. For four weeks, they administered it to male mice. The results showed that their sperm count had decreased. Pregnancy might have been avoided with a 99% success rate using YCT529. After quitting the treatment, the mice were able to procreate normally once more between four and six weeks.
No negative consequences were reported
No negative consequences, per the findings, were seen. Md Abdullah Al Noman of the University of Minnesota in Minneapolis stated to New Scientist magazine that the molecule demonstrated no harm when doses up to 100 times the effective dose were used. presented the findings of this study at the ACS Spring 2022 meeting in San Diego, California. The end of 2022 is the projected date for human clinical trials to evaluate the treatment's safety and effectiveness.
0 Commentaires